Regular monitoring of creatinine, haemoglobin and liver function tests (alkaline phosphatase or alanine aminotransferase) is recommended in European Association of Urology guidelines on metastatic disease and in concurrent Swedish guidelines on follow-up after hormone therapy (EAU, 2007; SBHW, 2007). This evidence concerns the gene GPT and metastatic neoplasm.